These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 28831942)

  • 1. PRICING, REIMBURSEMENT, AND HEALTH TECHNOLOGY ASSESSMENT OF MEDICINAL PRODUCTS IN BULGARIA.
    Benisheva-Dimitrova T; Sidjimova D; Cherneva D; Kralimarkov N
    Int J Technol Assess Health Care; 2017 Jan; 33(3):365-370. PubMed ID: 28831942
    [TBL] [Abstract][Full Text] [Related]  

  • 2. INTRODUCTION OF HEALTH TECHNOLOGY ASSESSMENT FOR MEDICINES IN SLOVAKIA.
    Tesar T; Hloska A; Wawruch M; Lehocka L; Snopkova M; Masarykova L
    Int J Technol Assess Health Care; 2017 Jan; 33(3):345-349. PubMed ID: 28434416
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HEALTH TECHNOLOGY ASSESSMENT IN EVALUATION OF PHARMACEUTICALS IN THE CZECH REPUBLIC.
    Vostalová L; Mazelová J; Samek J; Vocelka M
    Int J Technol Assess Health Care; 2017 Jan; 33(3):339-344. PubMed ID: 28438231
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CURRENT ENVIRONMENT FOR INTRODUCING HEALTH TECHNOLOGY ASSESSMENT IN GREECE.
    Kani C; Kourafalos V; Litsa P
    Int J Technol Assess Health Care; 2017 Jan; 33(3):396-401. PubMed ID: 28756795
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug Policy in Bulgaria.
    Dimova A; Rohova M; Atanasova E; Kawalec P; Czok K
    Value Health Reg Issues; 2017 Sep; 13():50-54. PubMed ID: 29073988
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Historical overview of regulatory framework development on pricing and reimbursement of medicines in Bulgaria.
    Vassileva M; Kamusheva M; Manova M; Savova A; Tachkov K; Petrova G
    Expert Rev Pharmacoecon Outcomes Res; 2019 Dec; 19(6):733-742. PubMed ID: 30900482
    [No Abstract]   [Full Text] [Related]  

  • 7. Drug Policy in Greece.
    Yfantopoulos JN; Chantzaras A
    Value Health Reg Issues; 2018 Sep; 16():66-73. PubMed ID: 30195093
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early dialogue with health technology assessment bodies: a European perspective.
    Cuche M; Beckerman R; Chowdhury CA; van Weelden MA
    Int J Technol Assess Health Care; 2014 Dec; 30(6):571-8. PubMed ID: 25816822
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New Drug Reimbursement and Pricing Policy in Taiwan.
    Chen GT; Chang SC; Chang CJ
    Value Health Reg Issues; 2018 May; 15():127-132. PubMed ID: 29704659
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A DECADE OF HEALTH TECHNOLOGY ASSESSMENT IN POLAND.
    Lipska I; McAuslane N; Leufkens H; Hövels A
    Int J Technol Assess Health Care; 2017 Jan; 33(3):350-357. PubMed ID: 28720170
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DEVELOPMENT OF HEALTH TECHNOLOGY ASSESSMENT IN ROMANIA.
    Scintee SG; Ciutan M
    Int J Technol Assess Health Care; 2017 Jan; 33(3):371-375. PubMed ID: 28436346
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An Overview of the Reimbursement Decision-Making Processes in Bulgaria As a Reference Country for the Middle-Income European Countries.
    Kamusheva M; Vassileva M; Savova A; Manova M; Petrova G
    Front Public Health; 2018; 6():61. PubMed ID: 29556491
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug Policy in the Czech Republic.
    Skoupá J
    Value Health Reg Issues; 2017 Sep; 13():55-58. PubMed ID: 29073989
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HEALTH TECHNOLOGY ASSESSMENT IN CENTRAL-EASTERN AND SOUTH EUROPE COUNTRIES: BOSNIA AND HERZEGOVINA.
    Guzvic V; Catic T; Kostic M
    Int J Technol Assess Health Care; 2017 Jan; 33(3):390-395. PubMed ID: 28434417
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of health technology assessment in the process of implementation of the EU Transparency Directive: relevant experience from Central Eastern European countries.
    Kolasa K; Kalo Z; Zah V; Dolezal T
    Expert Rev Pharmacoecon Outcomes Res; 2012 Jun; 12(3):283-7. PubMed ID: 22812552
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug Policy in Romania.
    Radu CP; Pana BC; Furtunescu FL
    Value Health Reg Issues; 2018 Sep; 16():28-32. PubMed ID: 29704726
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmaceutical pricing and reimbursement in China: When the whole is less than the sum of its parts.
    Hu J; Mossialos E
    Health Policy; 2016 May; 120(5):519-34. PubMed ID: 27080345
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of health technology assessment on pharmaceutical reimbursement in selected middle-income countries.
    Oortwijn W; Mathijssen J; Banta D
    Health Policy; 2010 May; 95(2-3):174-84. PubMed ID: 20074829
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HEALTH TECHNOLOGY ASSESSMENT IN TURKEY.
    Kahveci R; Koç EM; Küçük EÖ
    Int J Technol Assess Health Care; 2017 Jan; 33(3):402-408. PubMed ID: 28595660
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Insight into reimbursement decision-making criteria in Bulgaria: implications for orphan drugs.
    Iskrov GG; Raycheva RD; Stefanov RS
    Folia Med (Plovdiv); 2013; 55(3-4):80-6. PubMed ID: 24712287
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.